The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis

doi:10.1016/j.biopsych.2013.09.023

Biological Psychiatry

Volume 75, Issue 4, 15 February 2014, Pages 300-306

https://doi.org/10.1016/j.biopsych.2013.09.023 Get rights and content

This review summarizes the epidemiologic evidence linking autoimmune diseases and psychosis. The associations between autoimmune diseases and psychosis have been studied for more than a half century, but research has intensified within the last decades, since psychosis has been associated with genetic markers of the immune system and with excess autoreactivity and other immune alterations. A range of psychiatric disorders, including psychosis, have been observed to occur more frequently in some autoimmune diseases, such as systemic lupus erythematosus and multiple sclerosis. Many autoimmune diseases involve multiple organs and general dysfunction of the immune system, which could affect the brain and induce psychiatric symptoms. Most studies have been cross-sectional, observing an increased prevalence of a broad number of autoimmune diseases in people with psychotic disorders. Furthermore, there is some evidence of associations of psychosis with a family history of autoimmune disorders and vice versa. Additionally, several autoimmune diseases, individually and in aggregate, have been identified as raising the risk for psychotic disorders in longitudinal studies. The associations have been suspected to be caused by inflammation or brain-reactive antibodies associated with the autoimmune diseases. However, the associations could also be caused by shared genetic factors or common etiologic components such as infections. Infections can induce the development of autoimmune diseases and autoantibodies, possibly affecting the brain. Autoimmune diseases and brain-reactive antibodies should be considered by clinicians in the treatment of individuals with psychotic symptoms, and even if the association is not causal, treatment would probably still improve quality of life and survival.

Section snippets

Prevalence of Autoimmune Diseases in People with Psychosis

The prevalence of hospital contacts with an autoimmune diseases in the general population is about 4%, based on a Nationwide Danish study, whereas the prevalence of schizophrenia is estimated to be around 1% worldwide 29, 30. A Danish population-based study on 7704 patients with schizophrenia showed that the relative risk of schizophrenia for an individual with a history of autoimmune disease, in themselves or in their family, was elevated by about 45%, and schizophrenia was associated with a

Associations between Celiac Disease and Psychosis

Gluten intake induces the production of antigliadin and transglutaminase antibodies by the immune system (34). A wide range of neurological complications are associated with antibodies to gliadin, even in the absence of autoimmune disease 35, 36, 37. In the 1950s and 1960s, clinicians noticed what seemed to be an unusually high occurrence of celiac disease in persons with schizophrenia 19, 20. In the 1960s, Dohan 38, 39 observed in epidemiologic studies that schizophrenia admissions during

Rheumatoid Arthritis and Psychosis

As early as the 1950s, investigators were puzzled by the apparent protective effect of schizophrenia for rheumatoid arthritis 17, 18, and more than a dozen studies have later confirmed the same negative association 33, 53, 54, 55. The timing of disease onset is much later for rheumatoid arthritis than for schizophrenia and bipolar disorder, making it unlikely that the occurrence of rheumatoid arthritis raises or lowers risk for schizophrenia and bipolar disorder. The negative association

Autoimmune Diseases of the Thyroid Gland and Psychosis

Some patients with autoimmune thyroid diseases also have psychiatric symptoms that have been associated with antithyroid antibodies (57). Both autoimmune thyrotoxicosis (Graves’ disease) and autoimmune thyroiditis have been associated with a raised risk of schizophrenia in Danish population-based studies 15, 32. The prevalence of autoimmune thyrotoxicosis among patients with schizophrenia was also increased in the population-based study from Taiwan (33). Furthermore, studies have indicated a

Type 1 Diabetes and Psychosis

Type 1 diabetes is associated with autoantibodies against glutamic acid decarboxylase (GAD) (subtype glutamic acid decarboxylase 65 with affinity to the pancreas), which may also show affinity toward GAD expressed in the brain (subtypes glutamic acid decarboxylase 65 and glutamic acid decarboxylase 67). Glutamic acid decarboxylase is involved in the formation of the central neurotransmitter gamma-aminobutyric acid (GABA) and GAD antibodies are also associated with neurological diseases, such as

Systemic Lupus Erythematosus and Psychosis

Studies indicate that between 14% and 75% of patients with systemic lupus erythematosus (SLE) experience neuropsychiatric symptoms, including psychosis (5). The neuropsychiatric symptoms are suspected to be induced by brain-reactive antibodies (63), including antibodies with affinity toward the anti-N-methyl-D-aspartate glutamate receptor in the brain 25, 64, 65, which is central to current pathophysiological theories of psychosis 27, 66. Approximately 40% of the neuropsychiatric SLE

Multiple Sclerosis and Psychosis

Multiple sclerosis has been associated with a broad range of psychiatric symptoms 68, 69. In multiple sclerosis, there is a large-scale infiltration of cells from the immune system into the brain parenchyma, as well as activation of the resident inflammatory cells, astrocytes, and microglial cells, which results in nerve damage (70). Multiple sclerosis has been associated with an increased risk of both schizophrenia, nonaffective psychosis, and bipolar disorder in Danish population-based

Autoimmune Hepatitis and Psychosis

Autoimmune hepatitis has been associated with a fivefold to sixfold increased risk of schizophrenia and nonaffective psychosis and also an elevated incidence of bipolar disorder (32). Furthermore, a family history of autoimmune hepatitis has been associated with schizophrenia and nonaffective psychosis (32). In a Danish study (15), it was noted that if a person had both an autoimmune hepatitis diagnosis and a hospital contact with infection, the risk of schizophrenia was increased by almost

Guillain-Barré Syndrome and Psychosis

The incidence of Guillain-Barré is increased both before and after a diagnosis with nonaffective psychosis and also in the delayed period more than 5 years after the diagnosis 31, 32. The increased risk of psychosis is confined to persons with a diagnosis of Guillain-Barré syndrome, as well as a hospital contact with infection (15). Interestingly, the ganglioside-specific antibodies that are present in patients with Guillain-Barré syndrome are suspected to be induced by molecular mimicry after

Psoriasis and Psychosis

Psoriasis has been associated with an increased risk of schizophrenia in population-based studies both from Denmark and Taiwan 15, 32, 33. The risk of nonaffective psychosis and bipolar disorder has also been increased in Danish studies 31, 32. Additionally, a family history of psoriasis has been associated with schizophrenia and nonaffective psychosis but not bipolar disorder (32). To the best of our knowledge, psoriasis has not been associated with brain-reactive antibodies, but within recent

Associations between Infections, Autoimmune Diseases, and Psychosis

Infections are among the prime candidates for initiating autoimmune diseases (75) and have also been associated with the development of schizophrenia 15, 16 and bipolar disorder (76). A nationwide Danish study on persons with autoimmune diseases showed that the increased risk of schizophrenia diminished from 45% to 29% when restricted to persons without a history of infection (15). Additionally, the study found that when autoimmune diseases and severe infections occurred together, they

Associations with a Family History of Either Autoimmune Diseases or Schizophrenia

A family history of autoimmune diseases has been shown to increase the risk of schizophrenia by 10% and a family history of schizophrenia increases the risk of autoimmune diseases by 6% 31, 32. However, a family history of bipolar disorder was not significantly associated with autoimmune diseases and there was no association in the reverse direction 31, 32. A family history of the following specific autoimmune diseases was associated with an increased incidence of schizophrenia in the 2010

Brain-Reactive Antibodies and Psychosis

Since as early as the 1960s, autoantibodies with cross-reactivity against brain antigens have been described in the sera and CSF of patients with schizophrenia 21, 22, 23. Through the years, several groups have identified diverse brain-reactive antibodies in patients with schizophrenia, including antibodies against neurotransmitters, but consistency in the findings has not been high 5, 77, and the correlation with disease activity has been ambiguous (77). This could be due to differences in

Limitations

Most of the epidemiologic estimates are from register-based studies and the prevalence might be underestimated, since, in general, only diseases requiring hospital contacts are included. Diagnostic delay and undertreatment of somatic comorbidity are general problems for patients with schizophrenia 81, 82, 83 and possibly explain the increased mortality 83, 84. Therefore, the prevalence of autoimmune diseases might be much higher in screening studies of people with psychosis. Furthermore, if the

Views on the Nature of the Associations

Subgroups of people with schizophrenia may demonstrate features of an autoimmune process, and the hypothesis is strengthened by the findings of an increased familial association between autoimmune diseases and schizophrenia 24, 31, 60. Additionally, complex etiological mechanisms similar to those of some psychiatric disorders are hypothesized to be involved in the initiation of autoimmunity, where genetic susceptibility is required along with triggering events such as infections (77). Different

Conclusions

There is a positive association between a broad number of autoimmune diseases and autoantibodies with schizophrenia. Population-based studies from both Denmark and Taiwan have shown an association of a range of autoimmune diseases considered in aggregate and psychosis, including a specific positive association with celiac disease, autoimmune thyrotoxicosis, psoriasis, and pernicious anemia and a negative association with rheumatoid arthritis. Additionally, small associations between family

References (100)

H.V. Nikkila et al.
Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia
Schizophr Res
(2001)
B.J. Miller et al.
Meta-analysis of lymphocytes in schizophrenia: Clinical status and antipsychotic effects
Biol Psychiatry
(2013)
S. Potvin et al.
Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review
Biol Psychiatry
(2008)
J. Suvisaari et al.
Inflammation in psychotic disorders: A population-based study
Psychiatry Res
(2011)
B.N. van Berckel et al.
Microglia activation in recent-onset schizophrenia: A quantitative (R)-[11C]PK11195 positron emission tomography study
Biol Psychiatry
(2008)
M. Hadjivassiliou et al.
Gluten sensitivity: From gut to brain
Lancet Neurol
(2010)
F.C. Dohan
Wheat “consumption” and hospital admissions for schizophrenia during World War II. A preliminary report
Am J Clin Nutr
(1966)
F.C. Dohan
Coeliac disease and schizophrenia
Lancet
(1970)
J. Jackson et al.
A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies
Schizophr Res
(2012)
K.L. Reichelt et al.
Specific IgA antibody increases in schizophrenia
Biol Psychiatry
(1995)

D. Samaroo et al.

Novel immune response to gluten in individuals with schizophrenia

Schizophr Res

(2010)

F. Dickerson et al.

Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia

Biol Psychiatry

(2010)

R. Peleg et al.

“Bread madness” revisited: Screening for specific celiac antibodies among schizophrenia patients

Eur Psychiatry

(2004)

W.W. Eaton et al.

Schizophrenia and rheumatoid arthritis: A review

Schizophr Res

(1992)

O. Mors et al.

A population-based register study of the association between schizophrenia and rheumatoid arthritis

Schizophr Res

(1999)

E.F. Torrey et al.

The schizophrenia-rheumatoid arthritis connection: Infectious, immune, or both?

Brain Behav Immun

(2001)

C.M. Gilvarry et al.

Family history of autoimmune diseases in psychosis

Schizophr Res

(1996)

P. Wright et al.

Autoimmune diseases in the pedigrees of schizophrenic and control subjects

Schizophr Res

(1996)

G.O. Finney

Juvenile onset diabetes and schizophrenia?

Lancet

(1989)

D.A. Ballok

Neuroimmunopathology in a murine model of neuropsychiatric lupus

Brain Res Rev

(2007)

D.T. Balu et al.

Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia

Neurosci Biobehav Rev

(2011)

A. Minagar et al.

The destructive alliance: Interactions of leukocytes, cerebral endothelial cells, and the immune cascade in pathogenesis of multiple sclerosis

Int Rev Neurobiol

(2007)

A. Kimura et al.

High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases

J Neuroimmunol

(2010)

N.R. Rose

The role of infection in the pathogenesis of autoimmune disease

Semin Immunol

(1998)

C. Kowal et al.

Cognition and immunity; antibody impairs memory

Immunity

(2004)

U. Meyer et al.

Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond

Pharmacol Ther

(2011)

W.W. Eaton et al.

Epidemiology of autoimmune diseases in Denmark

J Autoimmun

(2007)

T.A. Bayer et al.

Evidence for activation of microglia in patients with psychiatric illnesses

Neurosci Lett

(1999)

M.S. Pedersen et al.

Schizophrenia in patients with atopic disorders with particular emphasis on asthma: A Danish population-based study

Schizophr Res

(2012)

S.Y. Yum et al.

Clinical perspectives on autoimmune processes in schizophrenia

Psychiatr Clin North Am

(2009)

S. Tanaka et al.

Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders

J Neuroimmunol

(2003)

C. Laske et al.

Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls

Psychiatry Res

(2008)

K. Schott et al.

Autoantibodies to serotonin in serum of patients with psychiatric disorders

Psychiatry Res

(2003)

K. Bechter et al.

Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: Identification of subgroups with immune responses and blood-CSF barrier dysfunction

J Psychiatr Res

(2010)

T.M. Laursen

Life expectancy among persons with schizophrenia or bipolar affective disorder

Schizophr Res

(2011)

M.E. Benros et al.

Autoimmune diseases and infections as risk factors for schizophrenia

Ann N Y Acad Sci

(2012)

A. Davidson et al.

Autoimmune diseases

N Engl J Med

(2001)

P.F. Sullivan et al.

Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies

Arch Gen Psychiatry

(2003)

J.H. Cho et al.

Genomics and the multifactorial nature of human autoimmune disease

N Engl J Med

(2011)

A.L. Jones et al.

Immune dysregulation and self-reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?

Immunol Cell Biol

(2005)

H. Stefansson et al.

Common variants conferring risk of schizophrenia

Nature

(2009)

Genome-wide association study identifies five new schizophrenia loci

Nat Genet

(2011)

N. Muller et al.

Immune system and schizophrenia

Curr Immunol Rev

(2010)

K. Radewicz et al.

Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics

J Neuropathol Exp Neurol

(2000)

M.E. Benros et al.

Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study

Am J Psychiatry

(2011)

R.H. Yolken et al.

Are some cases of psychosis caused by microbial agents? A review of the evidence

Mol Psychiatry

(2008)

R. Trevathan et al.

Rarity of concurrence of psychosis and rheumatoid arthritis in individual patients

J Nerv Ment Dis

(1953)

T. Pilkington

The coincidence of rheumatoid arthritis and schizophrenia

J Nerv Ment Dis

(1955)

L. Bender

Childhood schizophrenia

Psychiatr Q

(1953)

H. Graff et al.

Celiac syndrome in the case histories of five schizophrenics

Psychiatr Q

(1961)

Cited by (151)

Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia
2024, Schizophrenia Research
The clinical course following a first episode of schizophrenia (FES) is often characterized by recurrent relapses, resulting in unfavorable clinical and functional outcomes. Inflammatory dysregulation has been implicated in relapse risk; however, the predictive value of inflammatory blood cells in clinically remitted patients after a FES has not been previously explored.
In this study, we closely monitored 111 patients in remission after a FES until relapse or a three-year follow-up endpoint. The participants were recruited from the multicenter 2EPS Project. Data on inflammatory blood cells and ratios were collected at baseline and at the time of relapse or after three years of follow-up.
Monocyte counts (OR = 1.91; 95 % CI = 1.07–3.18; p = 0.009) and basophil counts (OR = 1.09; 95 % CI = 1.01–1.12; p = 0.005) at baseline were associated with an increased risk of relapse, while the platelet-lymphocyte ratio (OR = 0.98; 95 % CI = 0.97–0.99; p = 0.019) was identified as a protective factor. However, after adjusting for cannabis and tobacco use during the follow-up, only monocyte counts (OR = 1.73; 95 % CI = 1.03–2.29; p = 0.027) and basophil counts (OR = 1.08; 95 % CI = 1.01–1.14; p = 0.008) remained statistically significant. ROC curve analysis indicated that the optimal cut-off values for discriminating relapsers were 0.52 × 10^9/L (AUC: 0.66) for monocytes and 0.025 × 10^9/L (AUC: 0.75) for basophils. When considering baseline inflammatory levels, no significant differences were observed in the inflammatory biomarkers at the endpoint between relapsers and non-relapsers.
This study provides evidence that higher monocyte and basophil counts measured at remission after a FES are associated with an increased risk of relapse during a three-year follow-up period.
Cognitive and inflammatory heterogeneity in severe mental illness: Translating findings from blood to brain
2024, Brain, Behavior, and Immunity
Recent findings link cognitive impairment and inflammatory-immune dysregulation in schizophrenia (SZ) and bipolar (BD) spectrum disorders. However, heterogeneity and translation between the periphery and central (blood-to-brain) mechanisms remains a challenge. Starting with a large SZ, BD and healthy control cohort (n = 1235), we aimed to i) identify candidate peripheral markers (n = 25) associated with cognitive domains (n = 9) and elucidate heterogenous immune-cognitive patterns, ii) evaluate the regulation of candidate markers using human induced pluripotent stem cell (iPSC)-derived astrocytes and neural progenitor cells (n = 10), and iii) evaluate candidate marker messenger RNA expression in leukocytes using microarray in available data from a subsample of the main cohort (n = 776), and in available RNA-sequencing deconvolution analysis of postmortem brain samples (n = 474) from the CommonMind Consortium (CMC). We identified transdiagnostic subgroups based on covariance between cognitive domains (measures of speed and verbal learning) and peripheral markers reflecting inflammatory response (CRP, sTNFR1, YKL-40), innate immune activation (MIF) and extracellular matrix remodelling (YKL-40, CatS). Of the candidate markers there was considerable variance in secretion of YKL-40 in iPSC-derived astrocytes and neural progenitor cells in SZ compared to HC. Further, we provide evidence of dysregulated RNA expression of genes encoding YKL-40 and related signalling pathways in a high neuroinflammatory subgroup in the postmortem brain samples. Our findings suggest a relationship between peripheral inflammatory-immune activity and cognitive impairment, and highlight YKL-40 as a potential marker of cognitive functioning in a subgroup of individuals with severe mental illness.
The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia
2024, Psychiatry Research
Schizophrenia is a devastating psychiatric disorder that has detrimental effects on a significant portion of the global population. Electroconvulsive therapy (ECT), as a safe and effective physical therapy for schizophrenia, has demonstrated the ability to rapidly improve both positive and negative symptoms. Despite being used to treat schizophrenia for over 80 years, the therapeutic mechanisms of ECT are still in the early stages of exploration. Evidence has suggested that immune inflammation contributes to the pathogenesis of schizophrenia by interacting with neurotransmitters, neurodevelopment, and neurodegeneration. Given the importance of ECT as a fast-acting physical therapy for schizophrenia, gaining a deeper understanding of the role of immune inflammation may lead to developing innovative therapeutic approaches. This review summarized existing research that examined changes in peripheral inflammation following ECT in schizophrenia patients, and the effects of electroconvulsive stimulation (ECS) on neuroinflammation in animal studies.
Development of neuropsychiatry over the last 30 years and the new era of Immuno-Psychiatry
2023, Journal of Affective Disorders Reports
This is a narrative review about Neuropsychiatry, the development of Psychoneuroimmunology, and the progression to Immuno-Psychiatry (IP) over the last 30 years based on textbooks, journal articles and personal contributions.
Definitions, coverage and highlights in the development of neuropsychiatry document a change from focused individual organic diagnostic case reports to broader approaches (e.g., brain-mind relationships), or more specialized (e.g., neuroimaging perspective, neurogenetics, neuroplasticity) thereby achieving increasing clinical relevance, and advancing to recent highlights those being the developments in neurogenetics and psychoneuroimmunology. The latter has culminated in the emerging field of IP.
Basic new insights of IP include: a role for neuroinflammation in a spectrum of severe mental disorders, the consensus description of diagnosis and treatment of autoimmune psychosis (with outstanding clinical relevance), emerging findings of prevailing milder forms of neuroinflammation in severe mental disorders (SMD's) by emerging appropriate diagnostic methods (especially neuroimaging, CSF diagnostics), the role of environmental factors, especially infections, in the causality of SMD's. The interaction between genetic and environmental factors remains largely unresolved, with common pathophysiologic links possibly related to an IP constellation.
Gene expression profiling of monocytes in recent-onset schizophrenia
2023, Brain, Behavior, and Immunity
Immune–related mechanisms have been suggested to be involved in schizophrenia. Various studies have shown changes in monocytes isolated from the blood of schizophrenia patients, including changes in monocyte numbers, as well as altered protein and transcript levels of important markers. However, validation of these findings and understanding how these results are related to immune-related changes in the brain and schizophrenia genetic risk factors, is limited. The goal of this study was to better understand changes observed in monocytes of patients with early-onset schizophrenia. Using RNA sequencing, we analyzed gene expression profiles of monocytes isolated from twenty patients with early-onset schizophrenia and seventeen healthy controls. We validated expression changes of 7 out of 29 genes that were differentially expressed in previous studies including TNFAIP3, DUSP2, and IL6. At a transcriptome-wide level, we found 99 differentially expressed genes. Effect sizes of differentially expressed genes were moderately correlated with differential expression in brain tissue (Pearson’s r = 0.49). Upregulated genes were enriched for genes in NF-κB and LPS signaling pathways. Downregulated genes were enriched for glucocorticoid response pathways. These pathways have been implicated in schizophrenia before and play a role in regulating the activation of myeloid cells. Interestingly, they are also involved in several non-inflammatory processes in the central nervous system, such as neurogenesis and neurotransmission. Future studies are needed to better understand how dysregulation of the NF-κB and glucocorticoid pathways affects inflammatory and non-inflammatory processes in schizophrenia. The fact that dysregulation of these pathways is also seen in brain tissue, provides potential possibilities for biomarker development.
Association between autoimmune diseases of the nervous system and schizophrenia: A systematic review and meta-analysis of cohort studies
2023, Comprehensive Psychiatry
Numerous studies have found an association between autoimmune diseases of the nervous system (ADNS) and schizophrenia (SCZ), but the findings remain controversial. We conducted the first meta-analysis to summarize the current evidence from cohort studies that evaluated the association between ADNS and SCZ.
PubMed, Web of Science, and Embase were comprehensively searched until May 30, 2022 for articles on the association between ADNS and SCZ. Every included study was reported effect size with 95% CIs for the association between ADNS and SCZ. Meta-regression and subgroup analysis were used to assess the heterogeneity.
A total of 8 cohort studies with 12 cohorts were included in the meta-analysis. We observed a significant association between ADNS and SCZ (RR = 1.42; 95%CI, 1.18–1.72). Subgroup analysis showed that the risk of SCZ was significantly increased when ADNS were used as exposure factors (RR = 1.48; 95%CI, 1.15–1.89), whereas with SCZ did not observe an increased risk of subsequent ADNS (RR = 1.33; 95%CI, 0.92–1.92); multiple sclerosis (MS) was positively associated with SCZ (RR = 1.36; 95%CI, 1.12–1.66), but no significant association was found between Guillain-Barre syndrome (GBS) and SCZ (RR = 1.90; 95%CI, 0.87–4.17). Meanwhile, we found location was the source of heterogeneity.
High heterogeneity was observed (I² = 92.0%), and only English literature was included in the meta-analysis.
We found a positive association between ADNS and SCZ, and the association was different across the different types of ADNS. The results of the study are helpful for clinicians to carry out targeted preventive measures for ADNS and SCZ.

View all citing articles on Scopus

View full text

ReviewThe Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis

Section snippets

Prevalence of Autoimmune Diseases in People with Psychosis

Associations between Celiac Disease and Psychosis

Rheumatoid Arthritis and Psychosis

Autoimmune Diseases of the Thyroid Gland and Psychosis

Type 1 Diabetes and Psychosis

Systemic Lupus Erythematosus and Psychosis

Multiple Sclerosis and Psychosis

Autoimmune Hepatitis and Psychosis

Guillain-Barré Syndrome and Psychosis

Psoriasis and Psychosis

Associations between Infections, Autoimmune Diseases, and Psychosis

Associations with a Family History of Either Autoimmune Diseases or Schizophrenia

Brain-Reactive Antibodies and Psychosis

Limitations

Views on the Nature of the Associations

Conclusions

Schizophr Res

Biol Psychiatry

Biol Psychiatry

Psychiatry Res

Biol Psychiatry

Lancet Neurol

Am J Clin Nutr

Lancet

Schizophr Res

Biol Psychiatry

Schizophr Res

Biol Psychiatry

Eur Psychiatry

Schizophr Res

Schizophr Res

Brain Behav Immun

Schizophr Res

Schizophr Res

Lancet

Brain Res Rev

Neurosci Biobehav Rev

Int Rev Neurobiol

J Neuroimmunol

Semin Immunol

Immunity

Pharmacol Ther

J Autoimmun

Neurosci Lett

Schizophr Res

Psychiatr Clin North Am

J Neuroimmunol

Psychiatry Res

Psychiatry Res

J Psychiatr Res

Schizophr Res

Autoimmune diseases and infections as risk factors for schizophrenia

Ann N Y Acad Sci

Autoimmune diseases

N Engl J Med

Schizophrenia as a complex trait: Evidence from a meta-analysis of twin studies

Arch Gen Psychiatry

Genomics and the multifactorial nature of human autoimmune disease

N Engl J Med

Immune dysregulation and self-reactivity in schizophrenia: Do some cases of schizophrenia have an autoimmune basis?

Immunol Cell Biol

Common variants conferring risk of schizophrenia

Nature

Genome-wide association study identifies five new schizophrenia loci

Nat Genet

Immune system and schizophrenia

Curr Immunol Rev

Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics

J Neuropathol Exp Neurol

Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study

Am J Psychiatry

Are some cases of psychosis caused by microbial agents? A review of the evidence

Mol Psychiatry

Rarity of concurrence of psychosis and rheumatoid arthritis in individual patients

J Nerv Ment Dis

The coincidence of rheumatoid arthritis and schizophrenia

J Nerv Ment Dis

Childhood schizophrenia

Review
The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis